Moreover, ibrutinib leads to increased response of CD8+ T-cells in vitro and in vivo through inhibition of IL2-inducible T-cell kinase (ITK), and increases Th17 cells, leading to increased dendritic cell response and improved survival in CLL patients [159,160,199]. Here, ITK is linked to B-cell chronic lymphocytic leukemia.